# Biogen (BIIB) — Earnings

BIIB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/biib/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $3.60 |
| EPS estimate | $2.94 |
| EPS surprise | +22.49% |
| Revenue surprise | +11.20% |
| Revenue | $2.7B |
| Revenue estimate | $2.5B |
| Reported | Jul 29, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/875045/000087504526000075/biib-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/4b757a8c-f343-a8c0-c3da-2ecd9f2ee770.html) |

Biogen reported Q2 2026 results on July 29, 2026. Earnings per share came in at $3.60, ahead of the $2.94 estimate by 22.49%. Revenue was $2.7 billion, 11.20% above the $2.5 billion consensus. Compared with Q2 2025, EPS fell about 34% from $5.47, while revenue rose about 4% from $2.6 billion.

The longer record shows earnings moving within a range on flat sales. Annual EPS was $17.69 in 2022, $14.73 in 2023, $16.47 in 2024 and $15.29 in 2025. Annual revenue held between $9.8 billion and $10.1 billion over those four years. The first half of 2026 adds up to $7.17 per share, about 16% less than the same period a year earlier. Q2 2025 set the EPS high in the table at $5.47, and Q4 2025 was the low at $1.99. Over the last 20 quarters, Biogen topped the EPS estimate 18 times. The two misses were Q1 2022, at 16.59% below, and Q4 2023, at 7.35% below.

Biogen reported Q3 between October 20 and November 8 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue holds at the Q2 level.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 29, 2026 | $2.94 | $3.60 | 22.49% | $2.5B | $2.7B |
| Q1 2026 | Apr 29, 2026 | $3.08 | $3.57 | 15.77% | $2.3B | $2.5B |
| Q4 2025 | Feb 6, 2026 | $1.63 | $1.99 | 22.45% | $2.2B | $2.3B |
| Q3 2025 | Oct 30, 2025 | $3.88 | $4.81 | 23.89% | $2.3B | $2.5B |
| Q2 2025 | Jul 31, 2025 | $3.90 | $5.47 | 40.31% | $2.3B | $2.6B |
| Q1 2025 | May 1, 2025 | $2.90 | $3.02 | 4.16% | $2.2B | $2.4B |
| Q4 2024 | Feb 12, 2025 | $3.33 | $3.44 | 3.26% | $2.4B | $2.5B |
| Q3 2024 | Oct 30, 2024 | $3.77 | $4.08 | 8.15% | $2.4B | $2.5B |
| Q2 2024 | Aug 1, 2024 | $4.07 | $5.28 | 29.79% | $2.4B | $2.5B |
| Q1 2024 | Apr 24, 2024 | $3.47 | $3.67 | 5.78% | $2.3B | $2.3B |
| Q4 2023 | Feb 13, 2024 | $3.18 | $2.95 | -7.35% | $2.5B | $2.4B |
| Q3 2023 | Nov 8, 2023 | $3.97 | $4.36 | 9.73% | $2.4B | $2.5B |
| Q2 2023 | Jul 25, 2023 | $3.78 | $4.02 | 6.45% | $2.4B | $2.5B |
| Q1 2023 | Apr 25, 2023 | $3.28 | $3.40 | 3.72% | $2.3B | $2.5B |
| Q4 2022 | Feb 15, 2023 | $3.49 | $4.05 | 16.08% | $2.4B | $2.5B |
| Q3 2022 | Oct 25, 2022 | $4.13 | $4.77 | 15.61% | $2.5B | $2.5B |
| Q2 2022 | Jul 20, 2022 | $4.06 | $5.25 | 29.30% | $2.5B | $2.6B |
| Q1 2022 | May 3, 2022 | $4.34 | $3.62 | -16.59% | $2.5B | $2.5B |
| Q4 2021 | Feb 3, 2022 | $3.38 | $3.39 | 0.38% | $2.6B | $2.7B |
| Q3 2021 | Oct 20, 2021 | $4.09 | $4.77 | 16.73% | $2.7B | $2.8B |

## Frequently Asked Questions

### When did Biogen (BIIB) last report earnings?

Biogen last reported on Jul 29, 2026, covering fiscal Q2 2026.

### Did BIIB beat earnings estimates?

Yes. Biogen reported EPS of $3.60 for Q2 2026 against a $2.94 estimate — a 22.49% beat.

### How much revenue did BIIB report last quarter?

Biogen reported $2.7B in revenue for Q2 2026, against a consensus estimate of $2.5B.

## Similar Stocks

- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [IONS](https://www.lighthorse.io/tickers/ions) — Ionis Pharmaceuticals, Inc. - Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [PRTA](https://www.lighthorse.io/tickers/prta) — Prothena Corporation plc - Ordinary Shares
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock
- [BMY](https://www.lighthorse.io/tickers/bmy) — Bristol-Myers Squibb Company Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).